A simulation study of the strength of evidence in the recommendation of medications based on two trials with statistically significant results

Don van Ravenzwaaij and John P A Ioannidis

PLOS ONE, 2017, vol. 12, issue 3, 1-16

Abstract: A typical rule that has been used for the endorsement of new medications by the Food and Drug Administration is to have two trials, each convincing on its own, demonstrating effectiveness. “Convincing” may be subjectively interpreted, but the use of p-values and the focus on statistical significance (in particular with p

Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0173184 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 73184&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0173184

DOI: 10.1371/journal.pone.0173184

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().